Article

Topcon Europe invests in LensAR

Topcon Europe Medical BV has made an equity investment in LensAR, creating a long-term strategic cooperation that includes distribution and marketing of LensAR’s proprietary laser system in Europe.

Rotterdam, Netherlands, and Orlando-Topcon Europe Medical BV has made an equity investment in LensAR, creating a long-term strategic cooperation that includes distribution and marketing of LensAR’s proprietary laser system in Europe.

LensAR is a developer of a next-generation laser (LensAR Laser System) and 3-D imaging technology for refractive cataract surgery. The system is cleared by the FDA for anterior capsulotomy and lens fragmentation; for other indications, it is an investigational device in the United States.

“This is a very exciting opportunity for Topcon to demonstrate our commitment to technologies that will have a positive and significant impact on enhancing patient outcomes that are synergistic with our portfolio of products in ocular surgery, implants, and diagnostics,” said Eric Franken, managing director, Topcon Europe Medical BV. “This latest announcement shows our commitment and confidence in the [laser system] to expand our offering to our partner, the ophthalmic surgeon, and help us continue to combine our quality diagnostics with the newest surgical technologies.”

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.